Tempus AI Shares Fall 0.08% as $750M Volume Ranks 126th Amid Lawsuit Over Financial Misstatements and SoftBank Misrepresentation

Tempus AI (TEM) fell 0.08% on August 11, 2025, with a trading volume of $0.75 billion, a 53.24% decline from the prior day, ranking it 126th in market activity. The stock faces a class action lawsuit alleging securities law violations, with claims that the company inflated contract values, misrepresented joint venture credibility with SoftBank, and engaged in unethical billing practices through its acquisition of Ambry Genetics. The lawsuit further accuses Tempus of concealing risks tied to financial commitments from AstraZeneca and misleading public statements. Investors who purchased shares between August 6, 2024, and May 27, 2025, must seek lead plaintiff status by August 12.

Allegations include exaggerated revenue through self-funded agreements, unethical business practices post-Ambry acquisition, and a joint venture with SoftBank perceived to generate artificial revenue. The case highlights concerns over core operational weaknesses and financial transparency, potentially impacting investor confidence. A critical factor is a May 2025 report by Spruce Point Capital Management that exposed governance and reporting issues, triggering a prior significant price drop. The litigation underscores regulatory scrutiny on corporate disclosures and business ethics in the AI-driven healthcare sector.

The strategy of purchasing the top 500 stocks by daily trading volume and holding them for one day achieved a 166.71% return from 2022 to the present, outperforming the benchmark return of 29.18% by 137.53%. This highlights the effectiveness of liquidity concentration in capturing short-term momentum, particularly in volatile markets.